ArticleImmunotherapy2025
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma.
Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute rupture of primary hepatic angiosarcoma with Kasabach-Merritt syndrome: a rare case report and literature review.World journal of surgical oncology · 2025Review
- The diagnostic dilemma of sinusoidal-type primary hepatic angiosarcoma: A case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic angiosarcoma is a rare yet aggressive malignancy, which is prone to misdiagnosis due to the lack of specific molecular and radiological characteristics. The treatment regimens remain controversial and disappointing. Randomized clinical trials are limited due to the rarity of this specific aggressive malignancy. Independent case reports or series can provide relevant references for treatment. We reported the very first hepatic angiosarcoma received Atezolizumab and Bevacizumab as a first-line treatment prior to liver transplantation, which resulted in a partial pathological response under specific molecular mutations. This case illustrates the potential role of immune checkpoint inhibitor combined with anti-angiogenic therapy as an off-label treatment option warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.